chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Symptoms started on July 14th. What started as a pain in my left upper back, and felt like a pinched nerve, developed over the next 3 days into an excruciating pain that made it difficult to stand up. The pain was centered in my left scapular muscles and caused tingling, numbness, weakness and muscle spasms in my left tricep, back and pec. After about a week the pain started to subside but the weakness persisted. After a month of weakness and pain I noticed muscular atrophy in my left tricep, pec and scapular muscles. This is around the time I had my first visit with my orthopedic doctor.  XRays came back clear with no injuries, as did MRIs but EMG showed that there was nerve damage in my left tricep and pec. It wasn't until I saw a Dr. in early November of 2021 that she suggested that I had experienced Parsonage Turners Syndrome. Since then we have started physical therapy as treatment.
pt was asymptomatic @ time of vax; mom gave pt APAP 2:00 following vax; 5PM pt listless-deep sleep, shivering; was taken to hosp ER in youngstown; t103R; upon exam was found to have bilat ear infect;
scattered rashes; Rashes, redness on her face and neck; Itching all over the body; swelling of eyelids; Itching of ear; Redness of ear; Swelling of right ear; This is a spontaneous report from a contactable health care professional, the patient. A 31-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL0142; DOSE NUMBER: 1) via unspecified route of administration on the left arm on 31Dec2020 at 08:00 (at the age of 31-year-old at vaccination) as a single dose for COVID-19 vaccination. On 21Jan2021 at 11:00, the patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9262; DOSE NUMBER: 2) via unspecified route of administration in the left arm. Medical history of the patient included cholecystectomy in 2014. The patient was allergic to Norgestimate and Ethinyl estradiol (TRINESSA). Prior to vaccination, the patient was not diagnosed with COVID-19. Since vaccination, the patient was not tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received concomitant medications within 2 weeks prior to the COVID vaccine, but details were not provided. On 04Feb2021, the patient started having redness, itching and swelling on her right ear and continued on 05Feb2021. On 06Feb2021, it extended towards her upper cheeks. On 07Feb2021, event spread to left ear. On an unknown date, the patient also had swelling of eyelids, itching all over her body and scattered rashes. The patient took Cetirizine hydrochloride (ZYRTEC) for two days with no relief and switched to Diphenhydramine hydrochloride (BENADRYL) for two days and still had no relief. The patient went to the emergency department for fear of her throat closing, scheduled for a dermatologist who prescribed her a steroid cream (unspecified) for 2 weeks, which worked. But after 2 weeks, she had to stop the cream. Since then, she had nonstop itching all over her body. Patient also had intermittent swelling of eyes and, rashes, redness on her face and neck till the date of report. Any other antihistamine did not work for her. The clinical outcome of the events redness, itching and swelling on right ear, swelling of eyelids, itching all over her body, scattered rashes and, rashes, redness on face and neck was not resolved. No follow-up attempts are possible. No further information is expected.
This spontaneous report as received from a pharmacist via company representative refers to a female patient of unknown age. In 2007 the patient was vaccinated with a dose of ZOSTAVAX (dose, frequency, lot # and expiration date was not reported). On an unknown date, reported as "recently" the patient was diagnosed with shingles on the back of her leg. The outcome of shingles on the back of her leg was not reported. The relatedness between the event and ZOSTAVAX was not reported. Additional information has been requested.
Information has been received from a third party claims administrator for a pharmacy concerning a male patient. On an unspecified date the patient was vaccinated with PNEUMOVAX23 (lot #H021941 and expiration date 11JUL2014) and a flu vaccine (manufacturer not specified). On 05OCT2013 the patient experienced an adverse reaction (NOS) to PNEUMOVAX23 and the flu vaccine (manufacturer not specified). Per the reported, it was unclear which vaccine the patient had a reaction to. The outcome of the adverse reaction was unknown. Additional information has been requested.
Urticaria, pruritus and in area of injection 8 cm/6 cm erythema with several small areas of raised skin.
Pt noted right upper arm soreness, swelling and tissue "hardness" upon awakening on 7/15/10. During day soreness progressed to Rt upper arm pain. Area became itchy that evening. Saw site R.N. on 7/16/10. Area of induration 10cm x 7cm. Area of redness 15 cm x 7 cm. Afebrile. Tx'ed topical 1% hydrocortisone cream and LORATADINE 10mg p.o. Disp these OTC meds and BENADRYL 25mg for H.S. Employee returned for follow-up evaluation by the site occupational health nurse on 7/19/10 at 09:25 am: S: He states that arm where hepatitis B vaccine was injected had improved the morning of 7/17/10 and was fully resolved by the end of that day. He did not take any additional doses of LORATADINE after the initial dose give by this nurse on 7/16/10. He did not take any doses of BENADRYL over the weekend. He has a fading 1.5-cm bruise at injection site in right deltoid. Areas of redness and induration noted in the lateral upper arm on 7/16/10 have fully resolved.
From initial information received on 2/1/05 from a registered nurse regarding an adverse event, it was reported that a 54 year old male patient received his first dose of JE-VAX, lot number EJN212C, with the expiration date of 3/26/06, administered SC in the left arm on 1/25/05 at 10:40 AM. Two days later, the patient developed Bell's Palsy. The patient had no significant illness at the time of vaccination. He has a history of diabetes mellitus, gout, and hypertension. Reportedly, he did not recover from this event. (OMIC)
Several children, ages 6-16, were vax w/ booster dose;  During injection complained of severe stinging at the inject site;  the stinging persisted for minute.
Pt. turning in vaccine paper work for monitoring.  Pt kneeled on one knee.  Nurse went to side.  Pt. feel back, eyes rolled back not responding, snorted.  Rolled  on left side then come back, became aware of person, place and time.  EMT reported and observer the patient for 30 more minutes.  Vitals: BP 131/72, RR: 20, HR 71, OxSat 100%.
This spontaneous report as received from a certified medical assistant refers to a patient of unknown age and unknown gender. On 25-APR-2014 the patient was vaccinated with the first dose of GARDASIL, (strength and lot# unknown) injection, 0.5 ml, intramuscularly. The patient's dosing schedule of GARDASIL completed as followed: second dose 29-AUG-2012 and third dose 07-NOV-2012. No adverse effect reported. Additional information has been requested.
Developed fever (102.2), chills, body aches, joint pain, soreness at injection site, fatigue, headache, and nausea. Most severe symptoms lasted roughly 18 hours, then fever broke and chills stopped, while other symptoms persisted but more moderate level. 48 hours after injection, all symptoms stopped except for headache, fatigue, and moderate soreness at injection site. Now (55 hours) after injection, there is just some mild fatigue and mild soreness at injection site.
she doesn't remember anything that happened that day, until next day; felt fatigue; This spontaneous case was reported by a consumer and describes the occurrence of AMNESIA (she doesn't remember anything that happened that day, until next day) and FATIGUE (felt fatigue) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 24-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Jan-2021, the patient experienced AMNESIA (she doesn't remember anything that happened that day, until next day) and FATIGUE (felt fatigue). At the time of the report, AMNESIA (she doesn't remember anything that happened that day, until next day) and FATIGUE (felt fatigue) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       Patient took 2nd dose of Moderna COVID-19 Vaccine on 24-Feb-2021 and has no side effects. No concomitant medications information was reported. No treatment medications were provided.
Lump (bigger than a bean) tenderness, slight redness and warmth near L shoulder.
ADMINISTERED 0.3 ML OF UNDILUTED PEDIATRIC COVID BIVALENT VACCINE INSTEAD OF 0.3 ML OF ADULT COVID BIVALENT VACCINE, RESULTING IN EQUIVALENT DOSE OF 30 MCG BUT FROM INCORRECT VIAL
rash /more red; Rashes are more like a little pimples; arm kind of hurts; This spontaneous case was reported by an other health care professional and describes the occurrence of RASH ERYTHEMATOUS (rash /more red), DERMATITIS ACNEIFORM (Rashes are more like a little pimples) and MYALGIA (arm kind of hurts) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH ERYTHEMATOUS (rash /more red), DERMATITIS ACNEIFORM (Rashes are more like a little pimples) and MYALGIA (arm kind of hurts). At the time of the report, RASH ERYTHEMATOUS (rash /more red), DERMATITIS ACNEIFORM (Rashes are more like a little pimples) and MYALGIA (arm kind of hurts) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   concomitant medication was not provided treatment information was not provided
Expired vaccine used; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a 53-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031B21A) for COVID-19 vaccination.         On 29-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 29-Oct-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant products and treatment information were reported.
Light headed/dizzy.  Body aches all over. Severe arm pain at site radiating down arm.
Patient states she received 2 immunizations Dec. 3 07, which she believes caused inflammation and tenderness with dorsal aspect (L) shoulder and especially proximal - lateral (L) arm. We are referring to doctors as result of ongoing tenderness and decreased ROM.
I noticed a red splotchy rash on my arm at the injection site.  It showed up on Wednesday Feb 3, 9 days after my injection.  It is moderately itchy.
pt devel knee pain approx 5 days p/receiving MMR; examined 3 wks p/MMR @ that time had no joint swelling or clinical evidence of arthritis; recommended course of Ibuprofen; pt reports persistence of knee pain by phone 23JUL93;
The next morning I was having fever headache and sore arm, where the vaccine was I had  a sore arm and a rash that traveled down my arm. I was feeling better by the 3rd day except for the arm, that went on for a couple of days.
Child fainted about 1-2 minutes after last immunization was given. Child turned white, her eyes rolled back and she gasped. Child was laid down and she immediately woke up. She was kept prone with her feet elevelated for about 5 minutes. Once she was pink and communicating, she was kept in the waiting area for an additional 10 minutes before being allowed to leave the clinic.
Information has been received from a nurse concerning a male who on 30-OCT-2008 was vaccinated with PNEUMOVAX (Lot #62599/1076X), 0.5ml, intramuscularly.  Secondary suspect therapy included influenza virus vaccine (manufacturer unspecified) in the same arm on 30-OCT-2008.  On 31-OCT-2008, 1 day after the vaccination, the patient experienced redness at the injection site,
Fever Chills Narrative:  Woke up with temp of 101.7 day after receiving vaccine
Vomiting; This is a spontaneous report received from a contactable consumer (reporting for herself), via Pfizer-sponsored program. A female patient of an unspecified age received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, lot number and Expiration date was not reported) via an unspecified route of administration on an unspecified date of Jan2021 as a single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. On an unspecified date of Jan2021, patient had her first dose of the covid vaccine (a week ago), she wants to report their reaction series of vomiting on an unspecified date of Jan2021, 6 hours after receiving the first dose, 6x lasted 15 mins. The outcome of the event was unknown.  Information about batch/lot number has been requested.
02/16/22 presents to ED for "wheezing and increasing shortness of breath". PMHx of "asthma, CAD"
This spontaneous report as received from a medical assistant refers to an unknown number of patients of unknown age and gender. On unknown dates, the patients were inadvertently vaccinated with doses of M-M-R II (lots # L000458 exp date 06-JAN-2017, L012480 exp date 10-APR-2017 and L010488 exp date 26-MAR-2017) (route not reported) that were improperly stored. No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
Diagnosis of Trigeminal Nueralgia- Pain in my face and head on the left side.
Pt recvd vax & 2 days later had nose pain which progressed to jaw pain; pt was seen by MD who advised to take APAP;
PATIENT BRIEFLY LOST CONSCIOUSNESS(>1 MIN). REGAINED CONSCIOUSNESS AND HAD DISCOLORATION OF FACE AND LIPS. EMS WAS NOTIFIED.
On 7/29/08 mother of patient called and stated that her child was in extreme pain and arm was very swollen.  She was very upset and stated that it had never happened before and had said that it was administered incorrectly.  Appointment was set 7/30/08 and was seen by doctor and was determined to be an allergic reaction to the Varicella.
the following afternoon after my treatment I experienced shortness of breath, racing of the heart, headache, nausea, muscle ache, severe swelling and soreness in the are where the shot was given and fatigue.
1. throbbing headache to left side of head starting a few hours after injection, still present after 4 hours later so I took a Tylenol. 2. left arm pain when lifting up/use arm, starting 2-3 days later after injection, lasting 1-2 weeks and subside.
Chill, fatigue, muscle ache, sore at injection site. Lasted for one day. No treatments, medications  were  taken.
COVID Vaccine Breakthrough Case  Pfizer Dose 1 1/22/21 (lot NA) Pfizer Dose 2 2/12/21 (lot NA) COVID Positive 11/13/21  11/13/21: Patient is a resident of Skilled Nursing Facility brought to ER in the early morning of November 13th for shortness of breath and hypoxia, was reported home O2 saturation of 70% on room air.  According to ER physician there are multiple COVID positive patient at his nursing home, patient lost his sense of taste 1 week ago, denies any fevers or chills.  Patient was subsequently transferred to Medical Center for further care.  Currently patient is on 5 L of supplemental oxygen appears comfortable.  Patient states that he is a DNR/DNI but is okay with medical therapy.  11/20/21:  dramatically worsening  clinical condition noted, presently maxed out on medical therapies and is DNR  Patient family has been updated on patient's clinical condition, awaiting further decision with respect to initiation of comfort care measures   continue OptiFlow /OxyMask for supplemental oxygen therapy  Status post Actemra, Rocephin / azithromycin,  complete course of Decadron;  started on IV Zosyn for possible HCAP coverage per Pulmonary  Remdesivir precluded by renal function  Appreciate cardiology input, continue aspirin and metoprolol as recommended, scan to  assess probability of acute PE done yesterday reported as low probability  continue IV heparin for therapeutic anticoagulation in view of elevated D-dimer   urine output almost anuric despite Bumex drip, noted with worsening fluid volume overload now with anasarca  Monitor renal function,  strict ins and outs, avoid other nephrotoxic medications  Continue albumin infusion per Nephrology recommendations, diuretics  Optimize glycemic control  Continue other home medications as appropriate   prognosis is guarded His daughter/ POA called,  family decision has been made to proceed with comfort care measures.
Rash within 1 week of IZ with high fever consistent with measles like rash.
Lymphedema; Rashes that looked like little bubbles on her skin; had an allergic reaction to site; softball size welt; discoloration; itching/itching on her inner arms, upper chest and back; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 45-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 10Feb2021 16:00 (Lot number: EM9809) at the age of 44 years as dose 2, single for COVID-19 immunisation. Relevant medical history included: "Breast Cancer", start date: Nov2020 (unspecified if ongoing), notes: radiation treatment from 28Dec2020 to 26Jan2021; "Allergy to pineapple" (unspecified if ongoing); "Allergy to sulfas" (unspecified if ongoing); "Allergy to doxycycline" (unspecified if ongoing); "COVID-19" (unspecified if ongoing). Concomitant medication(s) included: TAMOXIFEN; PROTONIX; MICARDIS; LEXAPRO. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, Lot number: EI9263, Administration time=04:30 PM, Administration location=Left arm), administration date: 20Jan2021, when the patient was 44 years old, for COVID-19 Immunization. The following information was reported: LYMPHOEDEMA (non-serious) with onset Mar2021, outcome "unknown", described as "Lymphedema"; RASH (non-serious) with onset 2021, outcome "recovered" (2021), described as "Rashes that looked like little bubbles on her skin"; ADMINISTRATION SITE HYPERSENSITIVITY (non-serious) with onset 2021, outcome "recovered" (2021), described as "had an allergic reaction to site"; URTICARIA (non-serious) with onset 2021, outcome "recovered" (2021), described as "softball size welt"; SKIN DISCOLOURATION (non-serious) with onset 2021, outcome "recovered" (2021), described as "discoloration"; PRURITUS (non-serious) with onset 2021, outcome "recovered" (2021), described as "itching/itching on her inner arms, upper chest and back". The events "rashes that looked like little bubbles on her skin", "had an allergic reaction to site", "softball size welt", "discoloration" and "itching/itching on her inner arms, upper chest and back" were evaluated at the physician office visit.  Additional information: These events lasted about 2 months. The patient spoke to her dermatologist and internist in the spring and both were confused. The patient believed that there was a correlation. These events were not serious and did not result in death, caused/prolonged hospitalization, disabling/incapacitating and congenital anomaly/birth defect. Prior to vaccination, the patient was diagnosed as COVID-19. Since the vaccination, the patient had not been tested for COVID-19.   No follow-up attempts are needed. No further information is expected.
Redness, swelling, pain, and warmth at injection site with some redness and pain down the arm beginning the day after administration.  Patient has had significant improvement but has not had complete resolution.  There is still some redness and swelling at and near the injection site and some redness just below. She will seek medical attention if there is not continued improvement or complete resolution.
tested positive for Covid-19 today 16Dec21 from an at-home rapid test; tested positive for Covid-19 today 16Dec21 from an at-home rapid test; head cold; minor chills; Booster; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 38 year-old patient received bnt162b2 (BNT162B2), administration date 04Nov2021 (Batch/Lot number: unknown) at the age of 38 years as dose 3 (booster), single, (Batch/Lot number: unknown) as dose 1, single and (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), outcome "unknown", COVID-19 (medically significant) with onset 16Dec2021, outcome "unknown" and all described as "tested positive for Covid-19 today 16Dec21 from an at-home rapid test"; IMMUNISATION (medically significant) with onset 04Nov2021, outcome "unknown", described as "Booster"; NASOPHARYNGITIS (non-serious) with onset 15Dec2021, outcome "not recovered", described as "head cold"; CHILLS (non-serious) with onset 15Dec2021, outcome "not recovered", described as "minor chills". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (16Dec2021) positive; (16Dec2021) unknown result. Additional information: The patient reported that she/he had tested positive for Covid-19 today 16Dec21 from an at home rapid test. She/he had a PCR test done today and was awaiting results to confirm his/her positive result. She/he was instructed by the health department to report this positive test result as she/he was fully vaccinated and received a booster shot on 04Nov21. She/he was currently experiencing symptoms of a head cold, minor chills since yesterday 15Dec21. She/he was 38 years old and her/his date of birth was (Withheld). The lot number for bnt162b2 was not provided and will be requested during follow up.
Patient developed chest pain with elevated troponin levels 2 days after receipt of dose #2 of the Pfizer SARS-CoV2 vaccine.  He was admitted to the hospital with the diagnosis of myocarditis.
covid; covid; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 24-year-old male patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. There is no known allergies. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 02Aug2022, outcome "recovering" and all described as "covid". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (03Aug2022) Positive. Therapeutic measures were not taken as a result of drug ineffective, covid-19. Additional information: there is no other vaccine in fourweeks, no other medication in 2 weeks. There is no treatment for AE, no covid prior vaccination. Covid tested post vaccination with Nasal Swab on 03Aug2022, covid test result was positive.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.